Risk Factors for Visual Field Deterioration in the United Kingdom Glaucoma Treatment Study
RCT (n=516) found latanoprost reduced visual field deterioration by 58% vs placebo (HR, 0.42; 95% CI, 0.27–0.67; P = 0.001). Bilateral disease, higher intraocular pressure and disc haemorrhage were risk factors for deterioration; smoking history seemed to be protective.
Source:
American Journal of Ophthalmology
SPS commentary:
A National Institute of Health Research (NIHR) commentary notes that these findings support reducing eye pressure to preserve vision. Furthermore, the findings add to those from similar trials and NICE recommendations to offer eye drop treatments such as latanoprost, and possibly tafluprost and travoprost which also reduce pressure in the eye.